Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors.

ABSTRACT: The development of novel therapeutics that exploit alterations in the activation state of key cellular signaling pathways due to mutations in upstream regulators has generated the field of personalized medicine. These first-generation efforts have focused on actionable mutations identified by deep sequencing of large numbers of tumor samples. We propose that a second-generation opportunity exists by exploiting key downstream "nodes of control" that contribute to oncogenesis and are inappropriately activated due to loss of upstream regulation and microenvironmental influences. The RNA-binding protein HuR represents such a node. Because HuR functionality in cancer cells is dependent on HuR dimerization and its nuclear/cytoplasmic shuttling, we developed a new class of molecules targeting HuR

SUBMITTER: Filippova N 

PROVIDER: S-EPMC8137579 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature